Transactions
7
Insider / AbbVie Inc.
Davis Jennifer L.
Director at AbbVie Inc.
- Company
- AbbVie Inc.
- First filing on record
- October 2, 2025
- Latest trade on record
- May 8, 2026
- SEC filings
- EDGAR ↗
Davis Jennifer L., Director at AbbVie Inc., has disclosed 7 transactions in ABBV, PG since October 2, 2025: 0 purchases (0 open-market buys) and 2 sales, worth about $509K at the reported prices. The latest was filed May 12, 2026, 4 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
2
Avg. disclosure lag
4.7d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Davis Jennifer L. made no purchases and 1 sale worth $9K, plus 4 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Davis Jennifer L. has traded 1 stock on record; the largest by dollars is PG.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 3 | 70,021 | — |
| M | Option exercise or conversion | 2 | 121 | $8,723 |
| F | Shares withheld for tax | 1 | 60 | $8,723 |
| S | Open-market sale | 1 | 3,227 | $491K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 0 |
| 2025 | 6 | 0 | 2 · $500K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | Other A | May 8, 2026 | May 12, 2026 | 4d | 1,118 | — | — | Form 4 ↗ | ||
| PG | Option / conversion M | December 3, 2025 | December 5, 2025 | 2d | 60 | — | — | derivative | Form 4 ↗ | |
| PG | Other A | November 17, 2025 | December 5, 2025 | 18d | 34 | — | — | latederivative | Form 4 ↗ | |
| PG | Sell F | December 3, 2025 | December 5, 2025 | 2d | 60 | $144 | $8,723 | Form 4 ↗ | ||
| PG | Option / conversion M | December 3, 2025 | December 5, 2025 | 2d | 60 | $144 | $8,723 | Form 4 ↗ | ||
| PG | Sell S | October 2, 2025 | October 6, 2025 | 4d | 3,227 | $152 | $491K | Form 4 ↗ | ||
| PG | Other A | October 1, 2025 | October 2, 2025 | 1d | 68,869 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 12, 2026 | Form 4 | 0001916665-26-000002 | 1 | published | EDGAR ↗ |
| December 5, 2025 | Form 4 | 0000080424-25-000271 | 4 | published | EDGAR ↗ |
| October 6, 2025 | Form 4 | 0000080424-25-000204 | 1 | published | EDGAR ↗ |
| October 2, 2025 | Form 4 | 0000080424-25-000194 | 1 | published | EDGAR ↗ |
Other insiders at AbbVie Inc.
- Schulten Andre Chief Financial Officer 24 rows
- Aguilar Moses Victor Javier Chf Rsch, Dev & Innov Officer 22 rows
- Jejurikar Shailesh Chairman, President and CEO 21 rows
- Moeller Jon R Chairman, President and CEO 20 rows
- Hart Brett J Director 19 rows
- Purushothaman Balaji Chief Human Resources Officer 19 rows
- Whaley Susan Street Chief Legal Officer & Secy 19 rows
- Kempczinski Christopher J Director 18 rows
- ARNOLD CRAIG Director 17 rows
- Chang Amy Director 17 rows
Everyone on file, with contracts and lobbying under the company's name: AbbVie Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 7 | October 2, 2025 | May 12, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.